Todd Bazemore Sells 4,653 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Todd Bazemore sold 4,653 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total value of $22,101.75. Following the completion of the sale, the insider now directly owns 83,040 shares in the company, valued at $394,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Todd Bazemore also recently made the following trade(s):

• On Friday, May 31st, Todd Bazemore sold 2,093 shares of KALA BIO stock. The stock was sold at an average price of $6.09, for a total value of $12,746.37.

KALA BIO Price Performance

KALA stock opened at $6.45 on Friday. The stock’s 50 day simple moving average is $6.38 and its 200 day simple moving average is $7.02. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 4.92. KALA BIO, Inc. has a 12-month low of $4.21 and a 12-month high of $16.11.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($2.89) by ($1.31). Research analysts expect that KALA BIO, Inc. will post -14.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC purchased a new position in KALA BIO, Inc. (NASDAQ:KALA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO as of its most recent SEC filing. Institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

KALA has been the topic of a number of analyst reports. HC Wainwright dropped their price target on KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, May 17th. Oppenheimer reissued an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research report on Monday, April 1st.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.